Enzalutamide
ApprovedCompleted 1 views this week 0 watching⚡ Active
Interest: 43/100
43
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 2✓
Phase 35
ApprovedIndication / Disease
Metastatic Castration-resistant Prostate Cancer (mCRPC)
Conditions
Metastatic Castration-resistant Prostate Cancer (mCRPC)
Trial Timeline
Sep 25, 2013 → Jan 11, 2019
NCT ID
NCT01977651About Enzalutamide
Enzalutamide is a approved stage product being developed by Astellas Pharma for Metastatic Castration-resistant Prostate Cancer (mCRPC). The current trial status is completed. This product is registered under clinical trial identifier NCT01977651. Target conditions include Metastatic Castration-resistant Prostate Cancer (mCRPC).
What happened to similar drugs?
20 of 20 similar drugs in Metastatic Castration-resistant Prostate Cancer (mCRPC) were approved
Approved (20) Terminated (8) Active (0)
Hype Score Breakdown
Clinical
20
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (20)
| NCT ID | Phase | Status |
|---|---|---|
| NCT05404139 | Phase 2 | Recruiting |
| NCT02749903 | Phase 2 | Active |
| NCT02799745 | Phase 2 | Completed |
| NCT02750358 | Phase 2 | Active |
| NCT02605863 | Phase 2 | Terminated |
| NCT02384382 | Phase 2 | Completed |
| NCT02441517 | Approved | Terminated |
| NCT02507570 | Phase 2 | Completed |
| NCT02495974 | Pre-clinical | Completed |
| NCT02203695 | Phase 2 | Completed |
| NCT02288936 | Phase 2 | Completed |
| NCT02669771 | Pre-clinical | Completed |
| NCT02124668 | Phase 2 | Completed |
| NCT03297385 | Phase 2 | Completed |
| NCT02116582 | Approved | Completed |
| NCT02099864 | Phase 2 | Completed |
| NCT01977651 | Approved | Completed |
| NCT02138162 | Phase 1 | Completed |
| NCT01889238 | Phase 2 | Completed |
| NCT01663415 | Phase 2 | Withdrawn |
Competing Products
20 competing products in Metastatic Castration-resistant Prostate Cancer (mCRPC)